Antihypertensive drug class and adherence: An electronic monitoring study

American Journal of Hypertension

Volumn 28, Issue 6, 2015, Pages 717-721

  Moise, Nathalie ^a   Schwartz, Joseph ^a,b   Bring, Rachel ^a   Shimbo, Daichi ^a   Kronish, Ian M ^a  

^a Department of Medicine   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Blood pressure; Drug class; Hypertension; Medication adherence

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL PHARMACY; CONTROLLED STUDY; CONVENIENCE SAMPLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; EDUCATIONAL STATUS; ELECTRONIC MEDICAL RECORD; ETHNIC GROUP; FEMALE; HEALTH INSURANCE; HEART FAILURE; HOSPITAL MANAGEMENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; BLOOD PRESSURE; CLASSIFICATION; DRUG EFFECTS; ELECTRONIC PRESCRIBING; MEDICAL INFORMATION SYSTEM; MIDDLE AGED; PRIMARY HEALTH CARE; PROCEDURES; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL PHARMACY INFORMATION SYSTEMS; ELECTRONIC PRESCRIBING; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRIMARY HEALTH CARE; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84941564028     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpu199     Document Type: Article

References (20)

1. Horwitz RI, Viscoli CM, Berkman L, Donaldson RM, Horwitz SM, Murray CJ, Ransohoff DF, Sindelar J. Treatment adherence and risk of death after a myocardial infarction. Lancet 1990; 336: 542-545.
2. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012; 125: 882-887.
3. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 521-530.
4. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520.
5. Baggarly SA, Kemp RJ, Wang X, Magoun AD. Factors associated with medication adherence and persistence of treatment for hypertension in a Medicaid population [published online February, 2014]. RSAP doi: 10. 1016/j. sapharm. 2014. 02. 002.
6. Kronish IM, Woodward M, Sergie Z, Ogedegbe G, Falzon L, Mann DM. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation 2011; 123: 1611-1621.
7. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data. CMAJ 1999; 160: 41-46.
8. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510-e526.
9. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119: 3028-3035.
10. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
11. Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 2012; 52: 275-301.
12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
13. Beckett L, Godwin M. The BpTRU automatic blood pressure monitor compared to 24 hour ambulatory blood pressure monitoring in the assessment of blood pressure in patients with hypertension. BMC Cardiovasc Disord 2005; 5: 18.
14. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50: 105-116.
15. Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment-a review. Cardiovasc Diabetol 2009; 8: 18.
16. McGill JB. Optimal use of beta-blockers in high-risk hypertension: A guide to dosing equivalence. Vasc Health Risk Manag 2010; 6: 363-372.
17. National Prescription Audit, 2012. IMS Health Web Site. http: //www. imshealth. com. Updated March 22, 2013. Accessed September 15, 2014.
18. Frishman WH, Henderson LS, Lukas MA. Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction. Vasc Health Risk Manag 2008; 4: 1387-1400.
19. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 671-681.
20. Evans CD, Eurich DT, Lu X, Remillard AJ, Shevchuk YM, Blackburn D. The association between market availability and adherence to antihypertensive medications: An observational study. Am J Hypertens 2013; 26: 180-190.